Literature DB >> 23818754

Vancomycin-resistant Staphylococcus hominis endophthalmitis following cataract surgery.

Jun Yeon Won1, Moosang Kim.   

Abstract

We report a case of acute postoperative endophthalmitis caused by vancomycin-resistant Staphylococcus hominis, treated at our hospital. An 80-year-old male presented 2 days after uncomplicated phacoemulsification and posterior chamber intraocular lens implantation, with a 24-hour history of progressive visual loss and redness in the operated (right) eye. On examination, best corrected visual acuity was counting fingers. Anterior segment examination revealed conjunctival injection, chemosis, corneal edema, and hypopyon. B-scan ultrasonography showed vitreous opacification, but no retinal detachment. Acute postoperative endophthalmitis was diagnosed. We performed vitrectomy with vancomycin in the irrigating solution, intraocular lens removal, and silicone oil tamponade. Culture of the vitreous grew Staphylococcus hominis. Antibiotic susceptibility testing showed the isolate was sensitive to trimethoprim/sulfamethoxazole and teicoplanin but resistant to ciprofloxacin, moxifloxacin, levofloxacin, cefazolin, and vancomycin. At 3 months, the visual acuity of the silicone oil-treated eye was 20/400.

Entities:  

Keywords:  Staphylococcus hominis; endophthalmitis; vancomycin

Year:  2013        PMID: 23818754      PMCID: PMC3693842          DOI: 10.2147/OPTH.S46792

Source DB:  PubMed          Journal:  Clin Ophthalmol        ISSN: 1177-5467


Introduction

The incidence of infectious endophthalmitis after cataract surgery has been estimated to range from 0.07% to 0.13%.1 To our knowledge, there are no reports of vancomycin resistance to Staphylococcus hominis following endophthalmitis. We report a case of acute postoperative endophthalmitis caused by vancomycin-resistant S. hominis treated at our hospital.

Case report

An 80-year-old male presented 2 days after an uncomplicated phacoemulsification and implantation of a posterior chamber intraocular lens (IOL) (C-flex®; Rayner, Hove, UK), with a 24-hour history of progressive visual loss and redness in the operated (right) eye. Preoperative best-corrected visual acuity (BCVA) was 20/200 in the right eye. Past medical history was significant for hypertension, atrial fibrillation, and prostate cancer. On examination, the BCVA was counting fingers. Anterior segment examination revealed conjunctival injection, chemosis, corneal edema, and hypopyon (2 mm size). B-scan ultrasonography showed vitreous opacification but no retinal detachment (Figure 1). Acute postoperative endophthalmitis was diagnosed.
Figure 1

B-scan ultrasonography demonstrated vitreous opacities but no retinal detachment.

A vitreous biopsy was performed immediately, with an intravitreal injection of vancomycin 1.0 mg/0.1 mL and ceftazidime 2.25 mg/0.1 mL. Approximately 3 hours after the vitreous biopsy and intravitreal injection of antibiotics, an operating room became available, and we performed 23-gauge pars plana vitrectomy (PPV), using vancomycin in the irrigating solution, and IOL removal with the capsular bag. During the vitrectomy, we saw severe vitreous opacification and a thick exudative membrane that covered the entire retina. After delicate vitrectomy-like shaving, we could see the disc and major vessel arcade faintly. The vitreous humor obtained during the vitrectomy and IOL were sent to the laboratory for smear and culture test. Finally, we finished surgery after fluid−air exchange and silicone oil tamponade. Culture of the vitreous grew S. hominis. Antibiotic susceptibility testing (microbroth dilution MIC test) showed that the isolate was sensitive to trimethoprim/sulfamethoxazole (MIC sensitive [S] ≤2/38) and teicoplanin (S ≤4) but resistant to ciprofloxacin (MIC resistant [R] >2), moxifloxacin (R >4), levofloxacin (R >4), cefazolin (R >8), and vancomycin (R = 8~16). Postoperatively, the patient was treated with 2% teicoplanin eye drops, topical fortified vancomycin, and prednisolone acetate eye drops. At 3 months, the visual acuity of the silicone oil-treated eye was 20/400.

Discussion

S. hominis is normally found on human skin and is usually harmless but can sometimes cause infections in people with abnormally weak immune systems. Most, if not all, strains are susceptible to penicillin, erythromycin, and novobiocin, but a divergent strain, S. hominis subsp. novobiosepticus (SHN), was found recently.2 This strain was named so because of its unique resistance to novobiocin and its failure to produce acid aerobically, from trehalose and glucosamine. The S. hominis strains are also somewhat resistant to methicillin and gentamicin, and most strains are resistant to erythromycin, clindamycin, chloramphenicol, trimethoprim/sulfamethoxazole, and ciprofloxacin as well. The SHN strain seems to have thickened cell walls, and this tendency may be the result of a genetic background that also allows for vancomycin resistance.3 The SHN is so similar to the original S. hominis that a MicroScan system (Dade Behring, West Sacramento, CA, USA) is needed to differentiate the S. hominis and SHN in the clinical microbiology laboratory.4 However, unfortunately, our hospital did not have this equipment. Another point must be considered. Previously, Iyer et al reported that patients with S. hominis endophthalmitis have a subacute onset and are asymptomatic.5 However, the present case had an acute-onset postoperative endophthalmitis. In our case, a high-virulence organism and S. hominis may have presented as a mixed infection, and thus, it is possible that only S. hominis was cultured instead of the high-virulence organism. Asaoka studied the role of coagulase-negative staphylococci (CNS) in outer eye infections.6 Their results indicated that of 57 strains of CNS, only three (5.3%) strains belonged to S. hominis. Furthermore, these CNS were resistant to aminoglycoside and macrolide antibiotics, which are commonly used as eye drops for ocular infectious diseases. However, Asaoka suggested that ocular CNS infections can occur in immunologically compromised host patients. At 3 months, the visual acuity of the silicone oil-treated eye was 20/400. Although rare, we report that acute-onset, postoperative S. hominis endophthalmitis can occur in an immunocompetent patient.

Conclusion

We present a case of acute-onset, postoperative vancomycin-resistant S. hominis endophthalmitis managed with intravitreal antibiotics injection, PPV, IOL removal and silicone oil tamponade.
  6 in total

Review 1.  Risks of intravitreous injection: a comprehensive review.

Authors:  Rama D Jager; Lloyd Paul Aiello; Samir C Patel; Emmett T Cunningham
Journal:  Retina       Date:  2004-10       Impact factor: 4.256

2.  Staphylococcus hominis endophthalmitis associated with a capsular hypopyon.

Authors:  Mohan N Iyer; William J Wirostko; Steve H Kim; Kenneth B Simons
Journal:  Am J Ophthalmol       Date:  2005-05       Impact factor: 5.258

3.  [Role of Staphylococcus epidermidis in outer eye infections].

Authors:  I Asaoka
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1989-03

4.  Staphylococcus hominis subsp. novobiosepticus subsp. nov., a novel trehalose- and N-acetyl-D-glucosamine-negative, novobiocin- and multiple-antibiotic-resistant subspecies isolated from human blood cultures.

Authors:  W E Kloos; C G George; J S Olgiate; L Van Pelt; M L McKinnon; B L Zimmer; E Muller; M P Weinstein; S Mirrett
Journal:  Int J Syst Bacteriol       Date:  1998-07

5.  A sequence variant of Staphylococcus hominis with a high prevalence of oxacillin and fluoroquinolone resistance.

Authors:  J E Fitzgibbon; M D Nahvi; D T Dubin; J F John
Journal:  Res Microbiol       Date:  2001-11       Impact factor: 3.992

6.  Staphylococcus hominis subsp. novobiosepticus strains causing nosocomial bloodstream infection in Brazil.

Authors:  Izabel Cristina Vanzato Palazzo; Pedro A d'Azevedo; Carina Secchi; Antonio Carlos C Pignatari; Ana Lúcia da Costa Darini
Journal:  J Antimicrob Chemother       Date:  2008-09-04       Impact factor: 5.790

  6 in total
  7 in total

1.  Chronic Staphylococcus hominis endophthalmitis following injury with a retained intraocular foreign body.

Authors:  Y V Sychev; G A Vemulakonda
Journal:  Eye (Lond)       Date:  2014-09-05       Impact factor: 3.775

Review 2.  Endophthalmitis caused by Gram-positive organisms with reduced vancomycin susceptibility: literature review and options for treatment.

Authors:  Nidhi Relhan; Thomas A Albini; Avinash Pathengay; Ajay E Kuriyan; Darlene Miller; Harry W Flynn
Journal:  Br J Ophthalmol       Date:  2015-12-23       Impact factor: 4.638

3.  Update on the prevention and treatment of endophthalmitis.

Authors:  Stephen G Schwartz; Harry W Flynn
Journal:  Expert Rev Ophthalmol       Date:  2014-08-23

4.  Draft Genome Sequence of Staphylococcus hominis BHG17 Isolated from Wild Bar-Headed Goose (Anser indicus) Feces.

Authors:  Wen Wang; Si-Si Zheng; Kirill Sharshov; Hao Sun; Xian-Qiang Wu; Fang Yang; Xue-Lian Wang; Lai-Xing Li
Journal:  Genome Announc       Date:  2017-02-02

5.  Intracameral Bacteriophage Injection as Postoperative Prophylaxis for Enterococcus faecalis-Induced Endophthalmitis After Cataract Surgery in Rabbits.

Authors:  Tatsuma Kishimoto; Waka Ishida; Isana Nakajima; Takako Ujihara; Takashi Suzuki; Jumpei Uchiyama; Shigenobu Matsuzaki; Ken Fukuda
Journal:  Transl Vis Sci Technol       Date:  2022-04-01       Impact factor: 3.283

6.  Molecular basis of resistance to macrolides, lincosamides and streptogramins in Staphylococcus hominis strains isolated from clinical specimens.

Authors:  Ewa Szczuka; Nicoletta Makowska; Karolina Bosacka; Anna Słotwińska; Adam Kaznowski
Journal:  Folia Microbiol (Praha)       Date:  2015-08-09       Impact factor: 2.099

7.  Antibiotic Susceptibility of Biofilm Cells and Molecular Characterisation of Staphylococcus hominis Isolates from Blood.

Authors:  Soraya Mendoza-Olazarán; Rayo Morfín-Otero; Licet Villarreal-Treviño; Eduardo Rodríguez-Noriega; Jorge Llaca-Díaz; Adrián Camacho-Ortiz; Gloria M González; Néstor Casillas-Vega; Elvira Garza-González
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.